---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058655"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-05-11T20:10:52+00:00"
generated_at: "2026-05-11T22:18:03.588399+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance

## Summary
- U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.
- Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.
- First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.
- FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.
- Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M.

## SEC filing metadata
- accession: 0001104659-26-058655
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-05-11T20:10:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/0001104659-26-058655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/tm2614163d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058655
- JSON: https://secwatch.observer/filing/0001104659-26-058655.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058655.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.8 million, net income $13.1 million, or $0.50 per share, EPS $0.50 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: $14.8 million
  - Net income: $13.1 million, or $0.50 per share
  - EPS: $0.50 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights · Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarter · U.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarter ·
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/0001104659-26-058655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.